Digital PARP and DDR Inhibitors Summit 2021

Returning this year in a digital capacity, as the most comprehensive and definitive event in the field, the 4th Annual PARP and DDR Inhibitors Summit is proud to showcase the very latest case studies and unique perspectives from 20+ pioneering experts. This year is dedicated to the novel targeting of DNA Damage Response (DDR) pathways, optimizing the use of synthetic lethality, to develop safe and efficacious blockbuster therapies in multiple cancers.

Plan how to optimize PARP inhibitors in the clinic with treatment combinations to expand indications and deliver more selective, better tolerated medicines to improve survival rates in difficult-to-treat cancers.

This Summit is industry focused on, and dedicated to, bringing new and novel next generation DDR therapeutics to the clinic and capitalizing on the therapeutic application of PARP inhibitors by finding optimal treatment combinations and expanding its use in cancer indications. If you are a research team striving to create best-in-class DDR therapeutics, this is the specific networking forum which has been curated with you in mind.

URLs:
Tickets: https://go.evvnt.com/689930-0?pid=176
Brochure: https://go.evvnt.com/689930-2?pid=176

Prices:
Conference Only - Drug Developers: USD 1999.0,
Conference + 1 Workshop - Drug Developers: USD 2348.0,
Conference + 2 Workshops - Drug Developers: USD 2697.0,
Conference Only - Academic: USD 1749.0,
Conference + 1 Workshop - Academic: USD 2048.0,
Conference + 2 Workshops - Academic: USD 2347.0

Speakers: Ruth Plummer, Professor of Experimental Cancer Medicine, Newcastle University, John Tainer, Professor MD, Anderson Cancer Centre, Elaine Sanij, Senior Research Fellow, Peter MacCallum Cancer Centre, Karlene Cimprich, Professor of Chemical and Systems Biology, Stanford University, Tanja Stankovic, Professor - Cancer Genetics, University of Birmingham, Eric Brown, Associate Professor of Cancer Biology, University of Pennsylvania, Sotirios K. Sotiriou, Head of Biology and Co-Founder, FoRx Therapeutics, Andrea Loehr, Director - Translational Medicine, Clovis Oncology, Kent Mouw, Assistant Professor of Radiation Oncology, Dana-Farber Cancer Institute, Simon Boulton, Senior Group Leader, Francis Crick Institute Co-founder and VP Science Strategy, Artios Pharma, Petar Jelinic, Director, Translational Oncology and Clinical Biomarkers, Merck, Nicola Curtin, Professor of Experimental Cancer Therapeutics, Newcastle University, Elisabetta Leo, Principal Scientist, AstraZeneca, Graeme Smith, Chief Scientific Officer, Artios Pharma, Oren Gilad, Chief Executive Officer, Atrin Pharmaceuticals, Panagiotis Konstantinopoulos, Associate Professor of Medicine, Harvard Medical School, John Pollard, Global Head Early Clinical Development and Translational Medicine Oncology, Bayer, Nimrat Chatterjee, Assistant Professor, Univeristy of Vermont, Alan D'Andrea, Professor, Radiation Oncology, Harvard Medical School, Francoise Bono, Chief Scientific Officer, Onxeo, Geoffrey Shapiro, Director Early Drug Development Center, Dana-Faber Institute, Patrick Pilie, Assistant Professor, Genitourinary Medical Oncology MD, Anderson Cancer Center, Daniel Speidel, Co-Managing Director, Breakpoint Therapeutics, Helen Robinson, Head of Biology, Artios Pharma

Time: 09:00 - 17:00